Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Schachat AP, Wilkinson CP, Hinton DR, et al. Ryan's retina. 5th edition. 2013.
- Progress in inherited retinal disease drug discovery and development: a foundation's perspective.Pharm Res. 2018; 35: 239
- Clinical progress in inherited retinal degenerations: gene therapy clinical trials and advances in genetic sequencing.Retina. 2017; 37: 417-423
- Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease.Ophthalmology. 2017; 124: 1314-1331
- Close genetic linkage between X-linked retinitis pigmentosa and a restriction fragment length polymorphism identified by recombinant DNA probe L1.28.Nature. 1984; 309: 253-255
- RetNet: summaries of genes and loci causing retinal diseases.2019 (Available at:) (Accessed October 29, 2019)
- Utility of in vitro mutagenesis of RPE65 protein for verification of mutational pathogenicity before gene therapy.JAMA Ophthalmol. 2019; : 1-9https://doi.org/10.1001/jamaophthalmol.2019.3914
- Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus.Proc Natl Acad Sci U S A. 1997; 94: 6916-6921
- Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.Proc Natl Acad Sci U S A. 1996; 93: 11382-11388
- Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.Proc Natl Acad Sci U S A. 1997; 94: 10319-10323
- Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model.Hum Mol Genet. 2001; 10: 3075-3081
- Immunology of AAV-mediated gene transfer in the eye.Front Immunol. 2013; 4: 261
- Immune response following intraocular delivery of recombinant viral vectors.Gene Ther. 2003; 10: 977-982
- AAV-mediated gene therapy for retinal disorders in large animal models.ILAR J. 2009; 50: 206-224
- Retinal stem cell transplantation: balancing safety and potential.Prog Retin Eye Res. 2019; : 100779https://doi.org/10.1016/j.preteyeres.2019.100779
- Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration.Retina. 2019; 39: S2-S8
- Intraoperative use of microscope-integrated optical coherence tomography for subretinal gene therapy delivery.Retina. 2019; 39: S9-S12
- Stem cells in retinal regeneration: past, present and future.Development. 2013; 140: 2576-2585
- Gene therapy restores vision in a canine model of childhood blindness.Nat Genet. 2001; 28: 92-95
- Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.Lancet. 2017; 390: 849-860
- Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials.Ophthalmology. 2019; 126: 1273-1285
- The cone dystrophies.Eye (Lond). 1998; 12: 553-565
- CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia.Eur J Hum Genet. 2005; 13: 302-308
- CNGA3 mutations in hereditary cone photoreceptor disorders.Am J Hum Genet. 2001; 69: 722-737
- Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase.Science. 1993; 259: 377-381
- Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia.Nat Med. 2018; 24: 1507-1512
- Two-year results after AAV2-mediated gene therapy for choroideremia: the alberta experience.Am J Ophthalmol. 2018; 193: 130-142
- Choroideremia gene therapy phase 2 clinical trial: 24-month results.Am J Ophthalmol. 2019; 197: 65-73
- Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial.JAMA Ophthalmol. 2019; https://doi.org/10.1001/jamaophthalmol.2019.3278
- Complete exon-intron structure of the retina-specific ATP binding transporter gene (ABCR) allows the identification of novel mutations underlying Stargardt disease.Genomics. 1998; 48: 139-142
- Complement activation by bisretinoid constituents of RPE lipofuscin.Invest Ophthalmol Vis Sci. 2009; 50: 1392-1399
- Gene therapy for the treatment of X-linked retinitis pigmentosa.Expert Opin Orphan Drugs. 2018; 6: 167-177
- Nightstar announces planned initiation of phase 2/3 expansion study in XIRIUS trial for NSR-RPGR in XLRP and reports Third quarter 2018 financial results.(Available at:) (Accessed November 1, 2019)
Biogen announces agreement to acquire Nightstar therapeutics to establish clinical pipeline of gene therapy candidates in Ophthalmology. Accessed November 15, 2019. Available at: https://investors.biogen.com/news-releases/news-release-details/biogen-announces-agreement-acquire-nightstar-therapeutics.
- Vision tests in the mouse: functional phenotyping with electroretinography.Front Biosci (Landmark Ed). 2009; 14: 2730-2737
- Codon-optimized rpgr improves stability and efficacy of AAV8 gene therapy in two mouse models of X-linked retinitis pigmentosa.Mol Ther. 2017; 25: 1854-1865
- Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa.Hum Gene Ther Clin Dev. 2013; 24: 23-28
- Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial.Hum Genet. 2016; 135: 327-343
- Retinitis pigmentosa: genes and disease mechanisms.Curr Genomics. 2011; 12: 238-249
- AAV-mediated gene therapy halts retinal degeneration in PDE6beta-deficient dogs.Mol Ther. 2016; 24: 867-876
- Prevalence and geographical distribution of Usher syndrome in Germany.Graefes Arch Clin Exp Ophthalmol. 2002; 240: 495-498
- Ciliopathy: Usher Syndrome.Adv Exp Med Biol. 2018; 1085: 167-170
- Early findings in a Phase I/IIa clinical program for Usher syndrome 1B (USH1B; MIM #276900).Invest Ophthalmol Vis Sci. 2015; 56: 2286
- The natural history of congenital X-linked retinoschisis and conversion between phenotypes over time.Ophthalmol Retina. 2019; 3: 77-82
- Synaptic pathology and therapeutic repair in adult retinoschisis mouse by AAV-RS1 transfer.J Clin Invest. 2015; 125: 2891-2903
- Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase I/IIa trial by intravitreal delivery.Mol Ther. 2018; 26: 2282-2294
- AGTC. AGTC announces topline interim six-month data from phase 1/2 X-linked retinoschisis clinical study; termination of biogen collaboration.(Available at:) (Accessed October 30, 2019)
- Multiplex genome engineering using CRISPR/Cas systems.Science. 2013; 339: 819-823
- Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration.Mol Ther. 2017; 25: 1999-2013
- CRISPR/Cas9-mediated genome editing as a therapeutic approach for leber congenital amaurosis 10.Mol Ther. 2017; 25: 331-341
- Allergan and editas medicine initiate the brilliance phase 1/2 clinical trial of AGN-151587 (EDIT-101) for the treatment of LCA10.(Available at:) (Accessed November 1, 2019)
- Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10.Nat Med. 2019; 25: 229-233
- Gene therapy and genome surgery in the retina.J Clin Invest. 2018; 128: 2177-2188
- Antisense oligonucleotide therapy for inherited retinal dystrophies.Adv Exp Med Biol. 2016; 854: 517-524
- Antisense oligonucleotide (AON)-based therapy for leber congenital amaurosis caused by a frequent mutation in CEP290.Mol Ther Nucleic Acids. 2012; 1: e14
- Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.Proc Natl Acad Sci U S A. 2013; 110: E517-E525
- Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases.Proc Natl Acad Sci U S A. 2020; 117: 2710-2716
- Diagnostic yield of panel-based genetic testing in syndromic inherited retinal disease.Eur J Hum Genet. 2019; https://doi.org/10.1038/s41431-019-0548-5
- The oculome panel test: next-generation sequencing to diagnose a diverse range of genetic developmental eye disorders.Ophthalmology. 2019; 126: 888-907
- Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.Lancet. 2009; 374: 1597-1605
Article info
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
